文献速递类风湿关节炎

英夫利西单抗生物类似药PF-06438179/GP1111与参照药的随机双盲III期研究:第30至54周疗效、安全性与免疫原性

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54.
PubMed 文献 · RMD Open · 2019-03-28

REFLECTIONS B537-02为双盲、活性对照、多国研究,650例中重度活动性类风湿关节炎患者先随机接受PF-SZ-IFX或参照英夫利西单抗治疗30周;第30-54周PF-SZ-IFX组(n=280)继续原药,参照药组(n=286)按1:1再随机继续参照药(n=143)或换用PF-SZ-IFX(n=143)。结果显示三组疗效维持相当,第54周ACR20分别为71.1%、64.3%和70.6%,安全性与免疫原性总体可比,且第30周盲法换药未影响上述结果。

要点

  • 第54周ACR20:PF-SZ-IFX/PF-SZ-IFX 71.1%,ref-IFX/ref-IFX 64.3%,ref-IFX/PF-SZ-IFX 70.6%。
  • 治疗期不良事件发生率三组分别为36.8%、33.6%和37.8%,安全性特征无临床意义差异。
  • 第30周从参照药盲法换用PF-SZ-IFX后,疗效、安全性和免疫原性维持至第54周。

核心结论

  • PF-SZ-IFX与参照英夫利西单抗的疗效、安全性和免疫原性相似,维持至第54周,且第30周盲法换药未受影响。

研究设计与样本

  • REFLECTIONS B537-02为双盲、活性对照、多国研究,纳入650例中重度活动性类风湿关节炎患者。
  • 第1治疗期(0-30周)随机接受PF-SZ-IFX或参照英夫利西单抗;第2治疗期(30-54周)PF-SZ-IFX组(n=280)继续原药,参照药组(n=286)按1:1再随机继续参照药(n=143)或换用PF-SZ-IFX(n=143)。

主要发现

  • 第54周ACR20应答率:PF-SZ-IFX/PF-SZ-IFX组71.1%,ref-IFX/ref-IFX组64.3%,ref-IFX/PF-SZ-IFX组70.6%。
  • ACR50/70、DAS28-CRP缓解、DAS28-CRP平均变化和HAQ-DI等终点观察结果也相当。
  • 治疗期不良事件发生率:PF-SZ-IFX/PF-SZ-IFX组36.8%,ref-IFX/ref-IFX组33.6%,ref-IFX/PF-SZ-IFX组37.8%,组间安全性特征无临床意义差异。
  • 抗药抗体阳性率总体稳定且组间可比:PF-SZ-IFX/PF-SZ-IFX组52.1%(中和抗体80.8%),ref-IFX/ref-IFX组60.1%(中和抗体84.9%),ref-IFX/PF-SZ-IFX组58.0%(中和抗体78.3%)。

临床怎么用

  • 对于中重度活动性类风湿关节炎患者,PF-SZ-IFX可作为参照英夫利西单抗的生物类似药选择。
  • 从参照英夫利西单抗换用PF-SZ-IFX后,疗效、安全性和免疫原性维持稳定,支持临床换药决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the efficacy, safety and immunogenicity of PF-06438179/GP1111 (PF-SZ-IFX) compared with European reference infliximab (Remicade®; ref-IFX) in patients with moderate-to-severe, active rheumatoid arthritis after continued long-term use of PF-SZ-IFX, and in patients who were switched from ref-IFX to PF-SZ-IFX. METHODS: REFLECTIONS B537-02 was a double-blind, active-controlled, multinational study in which patients (N=650) were initially randomised to PF-SZ-IFX or ref-IFX for 30 weeks (treatment period [TP] 1). During weeks 30-54 (TP2), the PF-SZ-IFX group (n=280) continued treatment with PF-SZ-IFX (PF-SZ-IFX/PF-SZ-IFX) and patients in the ref-IFX group (n=286) were rerandomised (1:1) to continue ref-IFX (ref-IFX/ref-IFX) (n=143) or switch to PF-SZ-IFX (ref-IFX/PF-SZ-IFX) (n=143) for a further 24 weeks. Efficacy, safety, immunogenicity and pharmacokinetics were evaluated. RESULTS: During TP2, patients in all three treatment groups continued to maintain comparable treatment response. At week 54, the American College of Rheumatology (ACR20) response rates were 71.1% (PF-SZ-IFX/PF-SZ-IFX), 64.3% (ref-IFX/ref-IFX) and 70.6% (ref-IFX/PF-SZ-IFX). Observations for other endpoints, including ACR50/70, Disease Activity Score in 28 Joints Based on High-Sensitivity C Reactive Protein(DAS28-CRP) remission, and mean change in DAS28-CRP and Health Assessment Questionnaire-Disability Index, were also comparable. Treatment-emergent adverse events were reported in 36.8% (PF-SZ-IFX/PF-SZ-IFX), 33.6% (ref-IFX/ref-IFX) and 37.8% (ref-IFX/PF-SZ-IFX) of patients; there were no clinically meaningful differences in the safety profiles between groups. The percentage of patients who were antidrug antibody-positive was generally stable through the treatment period and comparable overall between the PF-SZ-IFX/PF-SZ-IFX (52.1%; neutralising: 80.8%), ref-IFX/ref-IFX (60.1%; neutralising: 84.9%) and ref-IFX/PF-SZ-IFX (58.0%; neutralising 78.3%) groups. CONCLUSIONS: The similar efficacy, safety and immunogenicity of PF-SZ-IFX compared with ref-IFX were maintained for up to 54 weeks and were not affected by blinded treatment switch from ref-IFX to PF-SZ-IFX at week 30. TRIAL REGISTRATION NUMBER: NCT02222493.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Alten R, Batko B, Hala T, et al. Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54. RMD Open. 2019. PMID: 30997153. doi:10.1136/rmdopen-2018-000876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。